Investing

89bio : ETNB

ETNB

Stock Data

$14.84

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

89bio Inc is a biopharmaceutical company based in San Francisco, California, focusing on creating treatments for liver and cardio-metabolic diseases. Its flagship product, pegozafermin, is in development to address conditions like nonalcoholic steatohepatitis and severe hypertriglyceridemia. Founded in 2018, 89bio is at the forefront of developing innovative therapies to meet critical healthcare needs.